Tesofensine for weight loss: what the evidence actually shows

What did @authentic_abi actually say?

Abi describes taking tesofensine at 500 mcg daily in capsule form, added to her existing regimen of sertraline 100 mg and tirzepatide. Her provider suggested tesofensine instead of increasing her sertraline dose, framing it as something that would help her body "create its own dopamine, create its own serotonin more naturally." She says it helped stabilize her mood through a difficult period and offered a secondary benefit of aiding weight loss alongside her tirzepatide.

She's transparent that her results are modest compared to what she's seen in other patients, and she frames the whole thing as a personal experience rather than a prescription for anyone else. That honesty is worth noting before we dig into what the science actually says, because some of the claims her provider apparently made deserve scrutiny.

Does the science back this up?

Partially, but the dopamine and serotonin framing is oversimplified in a way that could mislead people. Tesofensine is a triple monoamine reuptake inhibitor, meaning it blocks the reuptake of dopamine, serotonin, and norepinephrine. It does not cause the body to "create its own" neurotransmitters more naturally. It inhibits their removal from synapses, which is mechanistically similar to how SSRIs like sertraline work, just broader in scope.

On weight loss, the evidence is more solid. Astrup et al. (2008, The Lancet) published a randomized controlled trial showing tesofensine at 0.5 mg daily produced roughly 10.6% body weight reduction over 24 weeks versus 2.2% for placebo. That's meaningful. However, the drug also raised heart rate and blood pressure in that trial, a safety signal that didn't disappear in follow-up work. Tesofensine has never received FDA approval and remains investigational in the United States. Using it alongside an SSRI and a GLP-1 agonist creates a pharmacological stack with essentially no long-term safety data in humans.

What did they get wrong (or right)?

The claim that tesofensine helps the body create dopamine and serotonin "more naturally" is inaccurate, and this appears to be how Abi's provider explained it to her. Reuptake inhibition is not natural production. This distinction matters because patients making decisions based on that framing might underestimate the drug's potency or its overlap with their existing sertraline. Combining two drugs that both block serotonin reuptake raises the theoretical risk of serotonin syndrome, even if that risk at these doses is low.

What she got right: her description of tesofensine's dual role in mood and appetite regulation is broadly accurate. Hasselbalch et al. (2018, Obesity Reviews) noted tesofensine's central appetite-suppressing effects appear to be dopamine-mediated, which does align with some mood-adjacent benefits. Her acknowledgment that results vary by patient and that she's a "difficult, challenging patient" with complex comorbidities shows appropriate epistemic humility. She doesn't tell viewers to take tesofensine. That matters.

What should you actually know?

Tesofensine is not FDA-approved. In the United States, it's available only through compounding pharmacies, which means formulation, dosing, and purity are not standardized the way they are with approved medications. If you're considering it, the questions to ask your provider are specific: What is the cardiovascular monitoring plan? How does this interact with my current SSRI? Is there a titration protocol? What are the stopping criteria?

The combination of tesofensine plus an SSRI plus a GLP-1 agonist is not a stack with robust clinical trial data. That doesn't make it automatically dangerous, but it does mean you're in territory where your provider needs to be actively monitoring you, not just adding a capsule to your regimen. The Astrup 2008 trial remains the most cited efficacy data, and it used 0.5 mg doses with cardiovascular monitoring. Anyone starting this medication should be aware of the heart rate and blood pressure findings from that same trial.

• Tesofensine blocks reuptake of dopamine, serotonin, and norepinephrine. It does not increase natural production of these chemicals.
• Weight loss data from controlled trials is real and significant, but comes with cardiovascular caveats.
• No long-term safety data exists for tesofensine combined with SSRIs and GLP-1 agonists simultaneously.
• This is a compounded, non-FDA-approved drug in the U.S. Compounded versions are not equivalent to any approved product.